


# GeneSight®: Serving growing needs in Mental Health

Mark Verratti  
May 4, 2021





# Market increases five-fold

## Provider



Historical focus

16K Psychiatrists



Today's expanded target:

Over 100K high potential providers

## Patient



MDD


17M

ADHD

12M

Anxiety

15M



5M patients

with need for GeneSight® per year



# Pandemic transforming mental health needs

THE TIMES | MAY 2021 PAGE 1


**HEALTH NEWS**

## Dramatic Increase in Mental Health Doctor Visits

"Emerging data, historical studies and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. The pandemic has served to amplify personal, social and economic costs of mental illness to a magnitude that's unprecedented."

The COVID-19 pandemic may have lasting effects on the psychiatric care of patients, according to a presenter at the NEI Max Virtual Conference.

"The impact of the COVID-19 pandemic may go well beyond the physical complications," William M. Sauvé, MD, medical director of the Virginia region of Greenbrook TMS NeuroHealth Centers, said during a presentation. "Emerging data, historical studies and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. The pandemic has served to amplify personal, social and economic costs of



## The New York Times

Opinion

### The Hidden 'Fourth Wave' of the Pandemic

America hasn't begun to face this year's mental health crisis.

### The unspoken COVID-19 toll on the elderly: Loneliness

*"We can prevent and reverse loneliness with the power of our mind."*

## The New York Times

### The Pandemic Is a 'Mental Health Crisis' for Parents

New studies show caregivers with young children are stressed, with no signs of relief on the horizon.



HELP WANTED

### Mental health professionals are in high demand as the pandemic enters a second year



A woman with short, light-colored hair, wearing a white lab coat over a pink shirt, is looking through a microscope in a laboratory. The background is softly blurred, showing shelves with books and a warm, golden light source. The text "Expanding GeneSight® clinical utility" is overlaid on the left side of the image.

Expanding GeneSight® clinical utility



# New research supports GeneSight® clinical utility



## Published Data

### Blood Level Data

1,022 patients from GUIDED

Only GeneSight® predicted variation in patient outcomes

“GeneSight® was a better predictor than CPIC guidelines”

### Meta-analysis

1,556 patients - MDD & med failure

Evidence demonstrates improvement in all study endpoints

“Outcomes were significantly improved for patients with MDD whose care was guided by GeneSight test results compared with treatment-as-usual (TAU)”

## Coming Soon

### VA Study

2,000 patients comparing treatment with and without PGx in real-world setting

Enrollment completed


Results expected in first half of 2022

# Building momentum with GeneSight®



## Volume Drivers

- Market acceleration due to pandemic
- Strong growth in Primary Care
- Targeted go-to-market approach





Commercial transformation





# Expanding GeneSight® for ADHD

## Adding genes and medications tied to ADHD

Supported by in-vitro studies, literature reviews, and Medicare expanded coverage

Launching May 10<sup>th</sup>





# Embracing the new opportunity of telehealth

## GeneSight® at Home


### Program has delivered:

>60,000 cumulative orders through March 2021

~35% of Q1 orders




GeneSight® at Home orders






Recap





# Mental Health summary







 Myriad genetics